ORGANIGRAM GLOBAL INC (OGI.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:OGI - CA68617J1003 - Common Stock
2.21 CAD
+0.04 (+1.84%)
Overall OGI gets a fundamental rating of 3 out of 10. We evaluated OGI against 33 industry peers in the Pharmaceuticals industry. OGI may be in some trouble as it scores bad on both profitability and health. OGI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year OGI has reported negative net income.
- In the past year OGI has reported a negative cash flow from operations.
- OGI had negative earnings in each of the past 5 years.
- OGI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- OGI has a better Return On Assets (-4.40%) than 60.61% of its industry peers.
- OGI's Return On Equity of -7.09% is fine compared to the rest of the industry. OGI outperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -7.09% | ||
| ROIC | N/A |
ROA(3y)-32.94%
ROA(5y)-24.98%
ROE(3y)-37.82%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- OGI's Gross Margin of 6.64% is on the low side compared to the rest of the industry. OGI is outperformed by 75.76% of its industry peers.
- The Profit Margin and Operating Margin are not available for OGI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, OGI has more shares outstanding
- OGI has more shares outstanding than it did 5 years ago.
- OGI has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -0.31, we must say that OGI is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -0.31, OGI is in line with its industry, outperforming 51.52% of the companies in the same industry.
- OGI has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.22, OGI perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.31 |
ROIC/WACCN/A
WACC8.33%
2.3 Liquidity
- A Current Ratio of 2.26 indicates that OGI has no problem at all paying its short term obligations.
- OGI's Current ratio of 2.26 is fine compared to the rest of the industry. OGI outperforms 60.61% of its industry peers.
- A Quick Ratio of 1.28 indicates that OGI should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.28, OGI perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.26 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 60.25% over the past year.
- The Revenue has grown by 62.15% in the past year. This is a very strong growth!
- OGI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.46% yearly.
EPS 1Y (TTM)60.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.7%
Revenue 1Y (TTM)62.15%
Revenue growth 3Y21.14%
Revenue growth 5Y24.46%
Sales Q2Q%79.12%
3.2 Future
- The Earnings Per Share is expected to grow by 23.72% on average over the next years. This is a very strong growth
- OGI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.02% yearly.
EPS Next Y104.73%
EPS Next 2Y49.11%
EPS Next 3Y37.23%
EPS Next 5Y23.72%
Revenue Next Year22.53%
Revenue Next 2Y13.98%
Revenue Next 3Y10.71%
Revenue Next 5Y10.02%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- OGI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 193.13, OGI can be considered very expensive at the moment.
- The rest of the industry has a similar Price/Forward Earnings ratio as OGI.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, OGI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 193.13 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates OGI does not grow enough to justify the current Price/Earnings ratio.
- OGI's earnings are expected to grow with 37.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.11%
EPS Next 3Y37.23%
5. Dividend
5.1 Amount
- OGI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:OGI (1/20/2026, 7:00:00 PM)
2.21
+0.04 (+1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-16 2025-12-16/bmo
Earnings (Next)02-09 2026-02-09
Inst Owners7.7%
Inst Owner ChangeN/A
Ins Owners0.24%
Ins Owner ChangeN/A
Market Cap296.87M
Revenue(TTM)259.18M
Net Income(TTM)-24.76M
Analysts77.5
Price Target3.47 (57.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1338.94%
Min EPS beat(2)-2513.86%
Max EPS beat(2)-164.03%
EPS beat(4)1
Avg EPS beat(4)-540.26%
Min EPS beat(4)-2513.86%
Max EPS beat(4)916.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.78%
Min Revenue beat(2)3.01%
Max Revenue beat(2)8.56%
Revenue beat(4)3
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)8.56%
Revenue beat(8)5
Avg Revenue beat(8)0.68%
Revenue beat(12)6
Avg Revenue beat(12)-1.21%
Revenue beat(16)9
Avg Revenue beat(16)0.34%
PT rev (1m)13.33%
PT rev (3m)13.33%
EPS NQ rev (1m)62.96%
EPS NQ rev (3m)62.96%
EPS NY rev (1m)655.33%
EPS NY rev (3m)466.5%
Revenue NQ rev (1m)5.27%
Revenue NQ rev (3m)5.27%
Revenue NY rev (1m)6.43%
Revenue NY rev (3m)6.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 193.13 | ||
| P/S | 1.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.85 | ||
| P/tB | 1.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.24
EYN/A
EPS(NY)0.01
Fwd EY0.52%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS1.93
BVpS2.6
TBVpS1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -7.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.64% | ||
| FCFM | N/A |
ROA(3y)-32.94%
ROA(5y)-24.98%
ROE(3y)-37.82%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 94.85% | ||
| Cap/Sales | 6.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.26 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -0.31 |
F-Score4
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)85.08%
Cap/Depr(5y)98.16%
Cap/Sales(3y)9.58%
Cap/Sales(5y)15.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.7%
EPS Next Y104.73%
EPS Next 2Y49.11%
EPS Next 3Y37.23%
EPS Next 5Y23.72%
Revenue 1Y (TTM)62.15%
Revenue growth 3Y21.14%
Revenue growth 5Y24.46%
Sales Q2Q%79.12%
Revenue Next Year22.53%
Revenue Next 2Y13.98%
Revenue Next 3Y10.71%
Revenue Next 5Y10.02%
EBIT growth 1Y28.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year260.96%
EBIT Next 3Y67.83%
EBIT Next 5Y41.16%
FCF growth 1Y-1580.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-296.05%
OCF growth 3YN/A
OCF growth 5YN/A
ORGANIGRAM GLOBAL INC / OGI.CA FAQ
Can you provide the ChartMill fundamental rating for ORGANIGRAM GLOBAL INC?
ChartMill assigns a fundamental rating of 3 / 10 to OGI.CA.
Can you provide the valuation status for ORGANIGRAM GLOBAL INC?
ChartMill assigns a valuation rating of 1 / 10 to ORGANIGRAM GLOBAL INC (OGI.CA). This can be considered as Overvalued.
What is the profitability of OGI stock?
ORGANIGRAM GLOBAL INC (OGI.CA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ORGANIGRAM GLOBAL INC?
The Earnings per Share (EPS) of ORGANIGRAM GLOBAL INC (OGI.CA) is expected to grow by 104.73% in the next year.